• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Bisson Lori

    6/24/24 5:10:04 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bisson Lori

    (Last) (First) (Middle)
    21 WATERWAY AVENUE
    SUITE 300

    (Street)
    THE WOODLANDS TX 77380

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Autonomix Medical, Inc. [ AMIX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/21/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (Right to buy) $1.328 06/21/2024 A 377,221 (1) 06/21/2034 Common Stock 377,221 (2) 1,335,821 D
    Explanation of Responses:
    1. The option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
    2. Issued in connection with the reporting person's employment with the Company.
    /s/ Trent Smith, Attorney-in-Fact for Lori Bisson 06/24/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    SEC Filings

    View All

    SEC Form 424B3 filed by Autonomix Medical Inc.

    424B3 - Autonomix Medical, Inc. (0001617867) (Filer)

    12/12/25 5:00:27 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Autonomix Medical Inc.

    EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)

    12/12/25 12:15:06 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Autonomix Medical Inc.

    S-3 - Autonomix Medical, Inc. (0001617867) (Filer)

    11/26/25 5:02:11 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

    THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company's website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company's path forward: protecting the strength of its platform through intellectual property, and exploring new opportunities beyond its initial target, pancreatic cancer, into potential future targets in the cardiovascular space, pulmonary space as well as chronic pain. The CEO Corner segme

    11/26/25 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

    THE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,501,666 shares of common stock (or pre-funded warrants in-lieu thereof), and together with unregistered Series C warrants to purchase up to an aggregate 9,003,332 shares of common stock, in a private placement priced at the market under Nasdaq rules (the "Offering"). The combined effective offering price for each share of common stock (or pre-funded warrant in-lie

    11/18/25 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Medical, Inc. Reports Positive Subgroup Results Demonstrating Sustained Improvements in Quality of Life from Post Hoc Analysis of Pancreatic Cancer PoC Study

    EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study (Po

    11/17/25 8:00:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Hauser Bradley

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:19:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Capelli Christopher

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:16:29 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Klemp Walter V

    4 - Autonomix Medical, Inc. (0001617867) (Issuer)

    8/13/25 9:13:57 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    View All

    Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

    Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

    12/19/24 8:30:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

    Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

    6/17/24 4:05:00 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Autonomix Appoints Jennifer Cook as Chief Business Officer

    Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

    3/19/24 8:45:00 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    10/7/24 8:30:24 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care